BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2014 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

We performed a 5-question survey of 20 ophthalmologists who treat retinal diseases to gauge current usage and projected future usage of agents for the treatment of wet and dry age-related macular degeneration (AMD) and diabetic macular edema (DME).

Drugs and drug candidates discussed: Fovista, lampalizumab, Lucentis (ranibizumab), Eylea (aflibercept), Avastin (bevacizumab), and Ozurdex (dexamethasone-eluting implant).

To purchase the AMD and DME Survey, click the link at the top of the page.

For our disclosures, please read the BioMedTracker Research Standards.